Home > Publications database > Exogenous Hormone Use and Cutaneous Melanoma Risk in Women: The European Prospective Investigation Into Cancer and Nutrition. > print

001     144812
005     20240229123020.0
024 7 _ |a 10.1002/ijc.32674
|2 doi
024 7 _ |a pmid:31506954
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:66488992
|2 altmetric
037 _ _ |a DKFZ-2019-02237
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Cervenka, I.
|b 0
245 _ _ |a Exogenous Hormone Use and Cutaneous Melanoma Risk in Women: The European Prospective Investigation Into Cancer and Nutrition.
260 _ _ |a Bognor Regis
|c 2020
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1588843833_15569
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Jun 15;146(12):3267-3280
520 _ _ |a Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country-specific self-administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992-2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline-significant association between OC use and melanoma risk (HR=1.12, 95% CI=1.00-1.26), with no detected heterogeneity across countries (Phomogeneity =0.42). This risk increased linearly with duration of use (Ptrend =0.01). Among postmenopausal women, ever use of MHT was associated with a non-significant increase in melanoma risk overall (HR=1.14, 95% CI=0.97-1.43), which was heterogeneous across countries (Phomogeneity =0.05). Our findings do not support a strong and direct association between exogenous hormone use and melanoma risk. In order to better understand these relations, further research should be performed using prospectively collected data including detailed information on types of hormone, and on sun exposure, which may act as an important confounder or effect modifier on these relations. This article is protected by copyright. All rights reserved.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Al Rahmoun, M.
|b 1
700 1 _ |a Mahamat-Saleh, Y.
|b 2
700 1 _ |a Fournier, A.
|b 3
700 1 _ |a Boutron-Ruault, M. C.
|0 0000-0002-5956-5693
|b 4
700 1 _ |a Severi, G.
|b 5
700 1 _ |a Caini, S.
|b 6
700 1 _ |a Palli, D.
|b 7
700 1 _ |a Ghiasvand, R.
|0 0000-0002-5466-7308
|b 8
700 1 _ |a Veierod, M. B.
|b 9
700 1 _ |a Botteri, E.
|0 0000-0002-9023-8068
|b 10
700 1 _ |a Tjønneland, A.
|b 11
700 1 _ |a Olsen, A.
|b 12
700 1 _ |a Fortner, R. T.
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Kaaks, R.
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 14
|u dkfz
700 1 _ |a Schulze, M. B.
|b 15
700 1 _ |a Panico, S.
|b 16
700 1 _ |a Trichopoulou, A.
|b 17
700 1 _ |a Dessinioti, C.
|b 18
700 1 _ |a Niforou, K.
|b 19
700 1 _ |a Sieri, S.
|0 0000-0001-5201-172X
|b 20
700 1 _ |a Tumino, R.
|b 21
700 1 _ |a Sacerdote, C.
|0 0000-0002-8008-5096
|b 22
700 1 _ |a Bueno-de-Mesquita, B.
|b 23
700 1 _ |a Sandanger, T. M.
|b 24
700 1 _ |a Colorado-Yohar, S.
|b 25
700 1 _ |a Sánchez, M. J.
|b 26
700 1 _ |a Gil Majuelo, L.
|b 27
700 1 _ |a Lujan-Barroso, L.
|b 28
700 1 _ |a Ardanaz, E.
|b 29
700 1 _ |a Merino, S.
|b 30
700 1 _ |a Isaksson, K.
|b 31
700 1 _ |a Butt, S.
|b 32
700 1 _ |a Ljuslinder, I.
|b 33
700 1 _ |a Jansson, M.
|b 34
700 1 _ |a Travis, R. C.
|b 35
700 1 _ |a Khaw, K. T.
|b 36
700 1 _ |a Weiderpass, E.
|0 0000-0003-2237-0128
|b 37
700 1 _ |a Dossus, L.
|b 38
700 1 _ |a Rinaldi, S.
|0 0000-0002-6846-1204
|b 39
700 1 _ |a Kvaskoff, M.
|0 0000-0002-4557-3772
|b 40
773 _ _ |a 10.1002/ijc.32674
|g p. ijc.32674
|0 PERI:(DE-600)1474822-8
|n 12
|p 3267-3280
|t International journal of cancer
|v 146
|y 2020
|x 1097-0215
909 C O |o oai:inrepo02.dkfz.de:144812
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2017
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21